Imlifidase: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

1. Clinical implications of imlifidase interference in antibody screening and transfusion management.Transfusion · 2026
   Article
2. Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026
   Article
3. How to Cure Autoimmune GN and Podocytopathies.Journal of the American Society of Nephrology : JASN · 2026
   Review
4. Understanding the role of non-HLA antibodies in kidney transplantation: a literature review.Frontiers in immunology · 2026
   Review
5. Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.Results and problems in cell differentiation · 2026
   Review
6. The changing landscape of primary autoimmune neuropathies.Nature reviews. Neurology · 2025
   Review
7. Imlifidase: a new interferent on serum protein electrophoresis looking as a rare plasma cell dyscrasia.Clinical chemistry and laboratory medicine · 2025
   Article
8. Functional insights from recombinant production of bacterial proteases in Saccharomyces cerevisiae.Microbial cell factories · 2025
   Article
9. Translating B cell immunology to the treatment of antibody-mediated allograft rejection.Nature reviews. Nephrology · 2024
   Review
10. Imlifidase in kidney transplantation.Clinical kidney journal · 2024
    Article
11. Immunomodulating Enzymes fromMicroorganisms · 2024
    Review
12. The potential of bacterial anti-phagocytic proteins in suppressing the clearance of extracellular vesicles mediated by host phagocytosis.Frontiers in immunology · 2024
    Review
13. Therapy in the Course of Kidney Graft Rejection-Implications for the Cardiovascular System-A Systematic Review.Life (Basel, Switzerland) · 2023
    Review
14. The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.Haematologica · 2023
    Article
15. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Review
16. New approach to desensitization in solid organ transplantation-imlifidase.Frontiers in transplantation · 2022
    Review
17. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
18. Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies.Frontiers in immunology · 2021
    Review
19. Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.Frontiers in medicine · 2021
    Article
20. Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed?Xenotransplantation
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as